|Bid||119.56 x 1000|
|Ask||119.41 x 900|
|Day's Range||117.71 - 120.02|
|52 Week Range||96.99 - 134.55|
|Beta (3Y Monthly)||1.36|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.96 (0.84%)|
|1y Target Est||N/A|
Jeff Krumpelman, chief investment strategist and head of equities at Mariner Wealth Advisors, and Kenny Polcari, managing principal at Butcher Joseph Asset Management, join CNBC's "The Exchange" to discuss mid-day markets and the stocks they're watching.
Zimmer Biomet Holdings Inc NYSE:ZBHView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ZBH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZBH. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ZBH had net inflows of $3.63 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of March 31. In this […]
First quarter corporate report cards generally have been good, with 75% or so of S&P; 500 companies beating earnings estimates, observes John Buckingham, value investing expert and editor of The Prudent Speculator.
The Fed made a material reversal at year-end and lower interest rates have fueled gains for both stocks and bonds. Unprecedented technological innovation is driving impressive productivity gains which has helped to keep inflation in check. Where socialism grows so does inflation and stagnation.
On a per-share basis, the Warsaw, Indiana-based company said it had net income of $1.20. Earnings, adjusted for one-time gains and costs, came to $1.87 per share. The results surpassed Wall Street expectations. ...
With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet Holdings Inc (NYSE:ZBH) investors should be aware of a decrease in hedge fund sentiment in recent months. Zimmer Biomet Holdings Inc (ZBH) was in 36 hedge funds' portfolios at the end of the fourth quarter of 2018. There were 40 hedge funds in our database with ZBH positions at the end of the previous […]
With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.
Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.